SEC Charges Kentucky-Based Biopharmaceutical Company and Two Executives With Defrauding Investors
February 07, 2026
February 07, 2026
WASHINGTON, Feb. 7 -- The Securities and Exchange Commission issued the following litigation release (No. 26-cv-00042; E.D. Ky. filed Feb. 5, 2026):
* * *
Securities and Exchange Commission v. CBA Pharma, Inc., et al., No. 26-cv-00042 (E.D. Ky. filed Feb. 5, 2026)
On February 5, 2026, the Securities and Exchange Commission filed charges against CBA Pharma, Inc., a private Kentucky-based biopharmaceutical company; Wayne Michael Putnam, its president; and Lou . . .
* * *
Securities and Exchange Commission v. CBA Pharma, Inc., et al., No. 26-cv-00042 (E.D. Ky. filed Feb. 5, 2026)
On February 5, 2026, the Securities and Exchange Commission filed charges against CBA Pharma, Inc., a private Kentucky-based biopharmaceutical company; Wayne Michael Putnam, its president; and Lou . . .